Investor Relations
Vitro Diagnostics, Inc. (OTCPK:VODG)
Company Information
Vitro Biopharma4621 Technology Drive
Golden, CO 80403
303-999-2130
www.vitrobiopharma.com
Investor Relations
John EvansCFO & Director
[email protected]
(303) 999-2137
wwww.vitrobiopharma.com
Transfer Agent
Securities Transfer Corporation2591 Dallas Parkway, Suite 102
Frisco, TX 75034
469-633-0100
www.stctransfer.com
Share Statistics
Outstanding: 46,194,200(As of June 26th, 2018)
Press Releases
Vitro Biopharma 3rd Quarter Ended July 31st 2018 Financial Results of Operations.
Vitro Biopharma 3rd Quarter 2018 Financial Results of Operations Golden, Colorado-September 24th, 2018-Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro BioPharma, announced its 3rd quarter financial results of operations, ended July 31st, 2018. Vitro Diagnostics Inc....
read moreVitro Biopharma 2nd Quarter ended April 30th 2018 Financial Results of Operations
Golden, Colorado-June, 26th, 2018-Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its 2nd quarter ended April 30th 2018 financial results of operations. Vitro Diagnostics Inc. (“Vitro”) is pleased to announce a record 2nd quarter in Stem Cell...
read moreVitro Biopharma Debt Re-Capitalization and Executive Team Formation
Golden, Colorado-May 3rd, 2018-Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, (the “Company”) announced today the details of its balance sheet re-capitalization and the formation of its executive team effective April 30th , 2018. The Company’s founder and...
read moreVitro Biopharma 1st Quarter 2018 Financial Results of Operations
Golden, Colorado-March 20, 2018-Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its 1st quarter ended January 31st 2018 financial results of operations. Vitro Diagnostics Inc. (“Vitro”) is pleased to announce a record 1st quarter in Stem Cell...
read more2017 CEO Shareholder Letter: Translation from R&D to Stem Cell Therapies Accelerates Revenue and Prospects for Future Growth
Golden, Colorado—December 20, 2017—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its CEO letter to its shareholders including discussion of 2016 & 2017 results and plans for 2018 including regenerative medicine initiatives for expanding...
read moreVitro Biopharma Files Patent for its Novel Stem Cell Line with Broad Application to Stem Cell Therapies
Golden, Colorado—November 21, 2017 —Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced the filing of a USPTO patent application regarding a novel stem cell line and its application to treatment of a variety of conditions including skeletal muscular,...
read moreVitro Biopharma Reports Positive Clinical Trial Results of Stem Cell Activation Therapy for Autism
Golden, Colorado—August 8, 2017 —Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced initial results of a Phase I clinical trial testing the effects of its proprietary stem cell activation compounds for safety and efficacy in autistic patients....
read moreVitro Biopharma Receives Funding to Expand its Stem Cell Therapies
Golden, Colorado—March 29, 2017 —Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced the completion of a bridge loan in the amount of $125,000 and the execution of a Memorandum of Understanding (“MOU”) outlining the terms of a larger, subsequent...
read moreVitro Biopharma Files New Patents for Stem Cell Therapy of Neurological Conditions
Golden, Colorado—November 7, 2016 —Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced the filing of four new patent applications at the United States Patent Office seeking protection of its proprietary stem cell products and technology related to...
read moreVitro Biopharma Launches New Products to Advance Breast Cancer Treatment
Golden, Colorado—May 3, 2016 —Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced the launch of breast cancer CAFs (cancer-associated fibroblasts) that provide additional tools for drug discovery in the quest to eradicate cancer. CAFs reside within...
read more
Providing high quality commercialized cell lines, media, stem cell products & stem cell technology
Providing applications in stem cell research, drug discovery and STEM CELL therapies